Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
about
Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protectionPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionBabassu aqueous extract (BAE) as an adjuvant for T helper (Th)1-dependent immune responses in mice of a Th2 immune response-prone strain.Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.An overview on Leishmania vaccines: A narrative review article.Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c MiceImmunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer.Vaccine Development Against Leishmania donovani.Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.Delivery systems for Leishmania vaccine development.Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondiiThe effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in miceLiposomal adjuvant development for leishmaniasis vaccines.Identification and Biological Activity of Synthetic Macrophage Inducible C-Type Lectin Ligands.The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model.
P2860
Q27304818-D1F39F7F-4632-4DA8-9CC7-CDDF182FF5C7Q27305883-9C4E65A4-E4F7-47AF-9372-86260F995DC5Q33806434-65105B67-F89E-4124-A861-335878A797C8Q34639315-4EE1B85E-9CF3-429C-8B79-8EF60FEE27E4Q35517074-E6BF137C-83D6-4C15-B6C6-50AC247A4DDCQ37246219-5C519FEF-9FE1-4C62-B878-FA7B58389F17Q37347740-62F51673-C229-4B27-90F5-E6BD61FF176FQ38012112-92FC2546-F25C-49B9-AFD5-479EBEDF4088Q38028994-B5626663-7ECF-4AA0-86B0-BF639498AD5DQ38746362-2ED110EC-52F6-4D61-9248-B9D869F30587Q40159743-AA746A8E-24C9-4C76-922D-81D95FA0183DQ40548173-4935724B-B540-4538-B470-61DF192378CBQ47153161-240E71BC-2EC1-4DFE-AD08-7CCBF02A6BF9Q49413043-B7E2443B-04A5-48E6-959A-56721BCA21B7Q50054197-072AD152-303C-4E6B-AE9D-A2E43A17F7EF
P2860
Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@ast
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@en
type
label
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@ast
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@en
prefLabel
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@ast
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@en
P2093
P2860
P356
P1433
P1476
Comparison of BCG, MPL and cat ...... murine visceral leishmaniasis.
@en
P2093
Amrita Das
Rajesh Ravindran
Sudipta Bhowmick
P2860
P2888
P356
10.1186/1471-2180-10-181
P577
2010-06-24T00:00:00Z
P5875
P6179
1009264448